Beech Michael F
Known title: Executive Vice PresidentCIK: 0001626738
Associated companies
Transaction History
| BCO | ▼ Sell | Open Market | 9,066 | $583K | 3/10/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 2,338 | $154K | 3/10/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 6,200 | $406K | 3/10/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 4,896 | $318K | 3/10/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 7,510 | $507K | 3/9/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 7,158 | $478K | 3/9/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 1,492 | $101K | 3/9/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 6,340 | $427K | 3/9/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 516 | $34K | 3/1/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 398 | $26K | 2/24/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 315 | $20K | 2/20/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 11,487 | $606K | 2/17/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 9,474 | $606K | 2/17/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 793 | $51K | 2/17/2023 | View on chart |
| BCO | ▲ Buy | Grant | 3,624 | $0 | 2/16/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 1,494 | $95K | 2/16/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 2,263 | $134K | 12/3/2022 | View on chart |
| BCO | ▲ Buy | Grant | 3,927 | $0 | 3/1/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 657 | $47K | 2/24/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 287 | $20K | 2/21/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 315 | $22K | 2/20/2022 | View on chart |
| BCO | ▲ Buy | Grant | 2,220 | $0 | 2/17/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 926 | $64K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.